The First Trust Value Line Dividend Index Fund ETF (FVD) exhibits an implied analyst target price of $49.66, indicating a 9.84% upside from its recent trading price of $45.21. This projection is derived from the weighted average analyst 12-month forward targets of its underlying holdings, with significant contributions from components like Sanofi (SNY), Takeda Pharmaceutical (TAK), and Rio Tinto (RIO), which individually show over 20% potential upside to their analyst targets. This analysis suggests FVD has notable potential based on current analyst consensus for its constituents, prompting investors to assess the validity of these targets.
The First Trust Value Line Dividend Index Fund ETF (FVD) presents a potential valuation opportunity based on a bottom-up analysis of its constituents' consensus price targets. The ETF's weighted average implied analyst target price is $49.66, suggesting a 9.84% upside from its recent trading price of approximately $45.21. This potential is significantly driven by a few key holdings with substantial forecast returns, including Sanofi (SNY), Takeda Pharmaceutical (TAK), and Rio Tinto (RIO), which have implied upsides of 27.79%, 22.54%, and 21.66% to their respective analyst targets. While these figures indicate a bullish consensus on the ETF's core components, the analysis is accompanied by a note of caution, highlighting the need to question whether these targets are overly optimistic or based on outdated information. The divergence between the strong quantitative upside and the qualitative warning suggests that the value proposition hinges on the validity of the underlying analyst forecasts for these specific companies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
